GSK is doubling production of its AS01 adjuvant – used to boost the immune response to vaccines – for use in the malaria shot as it anticipates rising demand, and will work through its ...

Being the only product on the market, GSK’s vaccine has dominated the shingles ... and malaria jab Mosquirix (RTS,S/AS01), in addition to Shingrix. Most recently, Slaoui served as chief ...

The efficacy is also much higher than the 39% seen with GSK's Mosquirix (RTS,S/AS01), which was, nevertheless, deemed sufficient by the WHO to support a limited rollout to try to protect children ...

This RTS,S/AS01 (RTS,S) malaria vaccine is approved ... of research and development by the British pharmaceutical company, GlaxoSmithKline (GSK) through a partnership with the global public ...